Virax Biolabs Group Limited (VRAX)Stock Price & Financial Statements
AboutVirax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.Show more
- Revenue $6K -96.0%
- EBITDA -$6M +9.0%
- Net Income -$6M +10.0%
- EPS (Diluted) -1.95 +42.0%
- Gross Margin -838.21% -2691.7%
- EBITDA Margin -91920.87% -2148.9%
- Operating Margin -97344.76% -2243.8%
- Net Margin -95739.17% -2124.0%
- ROE -114.35% -19.2%
- ROIC -273.17% +58.7%
- Debt/Equity 0.07 +58.1%
- Interest Coverage -105.93 +56.2%
Key Insights
Based on financial data analysisStrengths
- ✓Company is almost debt free
- ✓Trading at only 0.1x book value
Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 5 (bottom 5%)
- ✗Sales declining 42.4% over 5 years
- ✗Shares diluted 54.7% in last year
- ✗Trading more than 30% below 52-week high
Price & Volume
Loading chart...
Growth Metrics
Revenue CAGR
10Y-
5Y-42.4%
3Y-
TTM293.05%
Profit (Net Income) CAGR
10Y-
5Y-
3Y-
TTM-78.54%
EPS CAGR
10Y-
5Y-
3Y-
TTM6.19%
ROCE
10Y Avg-117.16%
5Y Avg-117.16%
3Y Avg-117.16%
Latest-111.36%
Peer Comparison
Diagnostics and Omics Tools| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
 VCYTVeracyte, Inc. | 2.88B | 36.27 | 44.23 | 16.01% | 12.83% | 5.07% | 4.4% | 0.03 |
 ASBPWAspire Biopharma Holdings, Inc. | 178.9K | 0.02 | -0.01 | -16351.77% | ||||
VRAXVirax Biolabs Group Limited | 1.55M | 0.21 | -0.11 | -95.95% | -78.62% | -234.24% | 0.07 | |
 CDIOCardio Diagnostics Holdings, Inc. | 141.46M | 5.26 | -0.57 | 104.45% | -415.16% | -80.38% | 0.10 | |
 AIMDAinos, Inc. | 7.24M | 1.51 | -0.97 | -83.02% | -132.32% | -148.9% | 0.77 | |
 IMDXInsight Molecular Diagnostics Inc. | 95.47M | 5.47 | -1.17 | 25.15% | -13.81% | -14.81% | ||
 SEERSeer, Inc. | 103.2M | 1.85 | -1.33 | -8.13% | -486.02% | -29.19% | 0.08 | |
 ASBPAspire Biopharma Holdings, Inc. | 62.88M | 1.32 | -5.08 | -16351.99% |
Compare VRAX vs Peers
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
Income Statement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 99.88K | 123.82K | 0 | 8.56K | 156.42K | 6.33K |
| Revenue Growth % | - | 23.97% | -100% | - | 1727.11% | -95.95% |
| Cost of Goods Sold | 54.13K | 133.25K | 0 | 9.93K | 105.83K | 59.4K |
| COGS % of Revenue | 54.19% | 107.62% | - | 115.94% | 67.66% | 938.21% |
| Gross Profit | 45.75K | -9.43K | 0 | -1.36K | 50.59K | -53.07K |
| Gross Margin % | 45.81% | -7.62% | - | -15.94% | 32.34% | -838.21% |
| Gross Profit Growth % | - | -120.62% | 100% | - | 3806.23% | -204.9% |
| Operating Expenses | 696.99K | 635.1K | 1.73M | 5.73M | 6.55M | 6.11M |
| OpEx % of Revenue | 697.86% | 512.93% | - | 66947.74% | 4185.59% | 96506.56% |
| Selling, General & Admin | 609.99K | 514.88K | 1.3M | 5.33M | 4.59M | 4.33M |
| SG&A % of Revenue | 610.75% | 415.83% | - | 62309.16% | 2937.46% | 68394.06% |
| Research & Development | 87K | 120.22K | 433.74K | 397.11K | 1.56M | 1.78M |
| R&D % of Revenue | 87.11% | 97.09% | - | 4638.58% | 998.58% | 28112.49% |
| Other Operating Expenses | 2.47K | 266 | 0 | 0 | 390.36K | 0 |
| Operating Income | -651.24K | -644.54K | -1.73M | -5.73M | -6.5M | -6.16M |
| Operating Margin % | -652.05% | -520.55% | - | -66963.67% | -4153.25% | -97344.76% |
| Operating Income Growth % | - | 1.03% | -168.98% | -230.67% | -13.32% | 5.13% |
| EBITDA | 0 | -2 | -1 | -5.44M | -6.39M | -5.82M |
| EBITDA Margin % | - | -0% | - | -63570.74% | -4087.34% | -91920.87% |
| EBITDA Growth % | - | - | 50% | -99999900% | -17.48% | 8.98% |
| D&A (Non-Cash Add-back) | 651.24K | 644.54K | 1.73M | 0 | 103.1K | 343.39K |
| EBIT | -648.77K | -644.27K | -1.73M | -5.44M | -6.71M | -6.15M |
| Net Interest Income | -90.69K | -28.64K | 0 | -15.47K | -26.88K | -58.18K |
| Interest Income | 0 | 0 | 15.44K | 0 | 0 | 0 |
| Interest Expense | 90.69K | 28.64K | 15.44K | 15.47K | 26.88K | 58.18K |
| Other Income/Expense | -88.22K | -28.38K | -16.19K | 275K | -242.65K | -41K |
| Pretax Income | -739.46K | -672.91K | -1.75M | -5.46M | -6.74M | -6.2M |
| Pretax Margin % | -740.38% | -543.46% | - | -63751.47% | -4308.38% | -97992.31% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -136.66K |
| Effective Tax Rate % | 108.34% | 96.74% | 97.65% | 100% | 99.92% | 97.7% |
| Net Income | -801.13K | -650.98K | -1.71M | -5.46M | -6.73M | -6.06M |
| Net Margin % | -802.13% | -525.75% | - | -63748.32% | -4304.81% | -95739.17% |
| Net Income Growth % | - | 18.74% | -162.5% | -219.37% | -23.38% | 9.98% |
| Net Income (Continuing) | -739.46K | -672.91K | -1.75M | -5.46M | -6.74M | -6.07M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -159.03K | -181.13K | -222.13K | -222.4K | -227.98K | -233.97K |
| EPS (Diluted) | -0.70 | -0.57 | -1.50 | -5.13 | -3.36 | -1.95 |
| EPS Growth % | - | 18.57% | -163.16% | -242% | 34.5% | 41.96% |
| EPS (Basic) | -0.70 | -0.57 | -1.50 | -5.13 | -3.36 | -1.96 |
| Diluted Shares Outstanding | 1.14M | 1.14M | 1.14M | 1.06M | 2.01M | 3.1M |
| Basic Shares Outstanding | 1.14M | 1.14M | 1.14M | 1.06M | 2.01M | 3.1M |
| Dividend Payout Ratio | - | - | - | - | - | - |
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 22.61K | 39.62K | 48.71K | 9.63M | 4.38M | 4.89M |
| Cash & Short-Term Investments | 22.61K | 17.62K | 21.76K | 9.35M | 3.59M | 4.23M |
| Cash Only | 22.61K | 17.62K | 21.76K | 9.35M | 3.59M | 4.23M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 928 | 0 | 0 | 217.84K | 30.65K |
| Days Sales Outstanding | - | 2.74 | - | - | 508.33 | 1.77K |
| Inventory | 0 | 21.07K | 20.95K | 24.09K | 60.38K | 94.67K |
| Days Inventory Outstanding | - | 57.72 | - | 886.02 | 208.26 | 581.78 |
| Other Current Assets | 0 | 0 | 0 | 0 | 77.32K | 0 |
| Total Non-Current Assets | 0 | 54.5K | 0 | 178.4K | 1.1M | 1.53M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 1.1M | 1.53M |
| Fixed Asset Turnover | - | - | - | - | 0.14x | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 178.4K | 49.77K | 39.65K |
| Long-Term Investments | 0 | 54.5K | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | -178.4K | -49.77K | -39.65K |
| Total Assets | 22.61K | 94.12K | 48.71K | 9.81M | 5.48M | 6.43M |
| Asset Turnover | 4.42x | 1.32x | - | 0.00x | 0.03x | 0.00x |
| Asset Growth % | - | 316.29% | -48.25% | 20046.22% | -44.11% | 17.19% |
| Total Current Liabilities | 1.24M | 871.43K | 1.25M | 908.4K | 168.85K | 673.21K |
| Accounts Payable | 212.84K | 217.15K | 846.47K | 159.91K | 45.63K | 56.09K |
| Days Payables Outstanding | 1.44K | 594.79 | - | 5.88K | 157.38 | 344.69 |
| Short-Term Debt | 759.37K | 0 | 0 | 146.25K | 0 | 32.47K |
| Deferred Revenue (Current) | -759.37K | 0 | 0 | 38.25K | 0 | 0 |
| Other Current Liabilities | 11.47K | 192K | 3.76K | 140.29K | 63.12K | 60.48K |
| Current Ratio | 0.02x | 0.05x | 0.04x | 10.61x | 25.94x | 7.27x |
| Quick Ratio | 0.02x | 0.02x | 0.02x | 10.58x | 25.58x | 7.13x |
| Cash Conversion Cycle | - | -534.33 | - | - | 559.21 | 2K |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 176.34K | 291.54K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 176.34K | 291.54K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.24M | 871.43K | 1.25M | 908.4K | 345.19K | 964.75K |
| Total Debt | 759.37K | 179.48K | 3.76K | 146.25K | 224.3K | 377K |
| Net Debt | 736.76K | 161.86K | -18K | -9.21M | -3.36M | -3.85M |
| Debt / Equity | - | - | - | 0.02x | 0.04x | 0.07x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -7.18x | -22.50x | -112.30x | -370.62x | -241.70x | -105.93x |
| Total Equity | -1.22M | -777.32K | -1.2M | 8.9M | 5.14M | 5.46M |
| Equity Growth % | - | 36.03% | -53.95% | 844.04% | -42.29% | 6.29% |
| Book Value per Share | -1.07 | -0.68 | -1.05 | 8.38 | 2.56 | 1.76 |
| Total Shareholders' Equity | -1.06M | -596.18K | -974.58K | 9.13M | 5.37M | 5.7M |
| Common Stock | 104 | 265 | 999 | 1.56K | 2.57K | 4.34K |
| Retained Earnings | -3.98M | -4.63M | -6.34M | -11.79M | -18.53M | -24.59M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 2.92M | 4.03M | 5.36M | 20.92M | 23.89M | 30.28M |
| Minority Interest | -159.03K | -181.13K | -222.13K | -222.4K | -227.98K | -233.97K |
Cash Flow Statement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -744.61K | -590.19K | -809.07K | -4.18M | -6.25M | -4.56M |
| Operating CF Margin % | -745.54% | -476.65% | - | -48823.35% | -3993.77% | -72083.02% |
| Operating CF Growth % | - | 20.74% | -37.09% | -416.61% | -49.46% | 26.95% |
| Net Income | -739.46K | -650.98K | -1.71M | -5.46M | -6.74M | -6.07M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 103.1K | 343.39K |
| Stock-Based Compensation | 0 | 0 | 290.36K | 1.73M | 1.01M | 365.31K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 91.67K | 1.19K | -32.07K | -260.6K | 497.06K | 169.34K |
| Working Capital Changes | -96.82K | 59.61K | 644.39K | -216.28K | -1.12M | 625.62K |
| Change in Receivables | 0 | -928 | 928 | 0 | -217.84K | 219.66K |
| Change in Inventory | 0 | -21.07K | 121 | 20.95K | -60.38K | -34.29K |
| Change in Payables | -96.82K | 81.61K | 641.16K | 33.94K | -572.25K | 466.85K |
| Cash from Investing | 0 | 0 | 0 | -178.4K | -1.16M | -603.89K |
| Capital Expenditures | 0 | 0 | 0 | -178.4K | -952.5K | -603.89K |
| CapEx % of Revenue | - | - | - | 2083.9% | 608.94% | 9538.62% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -178.4K | -211.95K | 0 |
| Cash from Financing | 704.64K | 585.2K | 813.21K | 13.69M | 1.65M | 5.81M |
| Debt Issued (Net) | 0 | 0 | 100K | 146.25K | -206.27K | -107.76K |
| Equity Issued (Net) | 0 | 0 | 519.61K | 1000K | 234 | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 704.64K | 585.2K | 193.59K | -111.64K | 1.85M | 786.74K |
| Net Change in Cash | -39.97K | -4.99K | 4.13K | 9.33M | -5.76M | 639.7K |
| Free Cash Flow | -744.61K | -590.19K | -809.07K | -4.36M | -7.41M | -5.17M |
| FCF Margin % | -745.54% | -476.65% | - | -50907.25% | -4738.21% | -81621.64% |
| FCF Growth % | - | 20.74% | -37.09% | -438.66% | -70.06% | 30.28% |
| FCF per Share | -0.65 | -0.52 | -0.71 | -4.10 | -3.69 | -1.67 |
| FCF Conversion (FCF/Net Income) | 0.93x | 0.91x | 0.47x | 0.77x | 0.93x | 0.75x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 78.95K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Key Ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -141.62% | -95.9% | -114.35% |
| Return on Invested Capital (ROIC) | - | - | - | - | -662.2% | -273.17% |
| Gross Margin | 45.81% | -7.62% | - | -15.94% | 32.34% | -838.21% |
| Net Margin | -802.13% | -525.75% | - | -63748.32% | -4304.81% | -95739.17% |
| Debt / Equity | - | - | - | 0.02x | 0.04x | 0.07x |
| Interest Coverage | -7.18x | -22.50x | -112.30x | -370.62x | -241.70x | -105.93x |
| FCF Conversion | 0.93x | 0.91x | 0.47x | 0.77x | 0.93x | 0.75x |
| Revenue Growth | - | 23.97% | -100% | - | 1727.11% | -95.95% |
Deep Dive Analysis
Explore detailed financial history, valuation models, and returns analysis
Valuation Overview
DCF models, peer multiples & analyst estimates
Total Return Calculator
Historical returns with dividends reinvested
Dividend History
Yield, growth, payout safety & DRIP calculator
Earnings History
EPS trends, net income & profitability analysis
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of valuation, profitability & efficiency metrics